TGFB1 and neoplasm: This novel platform, in addition to its capabilities of generating reactive species, facilitating ICD, and diminishing the levels of TGF-β within the intratumoral milieu, distinctively emphasizes the reduction of tumor rigidity conferred by Bi-nMOF treatment.